Ramírez NC, Hernández SI

Language: Spanish
References: 21
Page: 199-205
PDF size: 466.91 Kb.

ABSTRACT

The cystic fibrosis (CF) is a disease with a multisystemic affection, with an autosomal recessive inheritance, caused by a mutation in a gene that encodes for the CF transmembrane conductance regulator (CFTR) protein, which acts mainly as a chloride channel; also with other functions as inhibiting the sodium transport in their epithelial channels, the regulation of the ATP channels, exchange of chloride-bicarbonate; among others. This revision is emphasized in the management of the pulmonary treatment as well as the diagnostic.

REFERENCES

1. Bonestroo H, Winter-de Groot K, Van der Ent C, Arets H. Upper and lower airway cultures in children with cystic fibrosis: Do not neglect the upper airways. J Cyst Fibros 2010; 9: 130–4.

2. Boussaud V, Guillemain R, Grenet D, Coley N, Souilamas R, Bonnette P, Stern M. Clinical outcome following lung transplantation in patients with cystic fi-brosis colonised with Burkholderia cepa-cia complex: results from two French centres. Thorax, 2008; 63: 732-7.

3. Castellani C, Southern K. European best practice guidelines for cystic fibrosis neonatal screening. J Cyst Fibros 2009; 8: 153–173.

4. Culling B, Ogle R. Genetic Counselling Issues in Cystic Fibrosis. Paediatr Respir Rev 2010; 11: 75–9.

5. Donaldson S, Bennett W, Zeman K, Knowles M, Tarran R. Mucus clearance and lung function in cystic fibrosis with hypertonic saline. NEJM 2006; 354: 241–50.

6. Konstan M, Byard P, Hoppel C, Davis P. Effect of high-dose ibuprofen in patients with cystic fibrosis. NEJM 1995; 332: 848–54.

7. Kreindler J. Cystic fibrosis: Exploiting its genetic basis in the hunt for new therapies. Pharmacol Ther 2010; 125: 219–29.

8. Liou T, Elkin E, Pasta D, Jacobs J, Konstan M. Year-to-year changes in lung function in individuals with cystic fibrosis. J Cyst Fibros 2010; 9: 250–6.

9. Mordant P, Bonnette P. Advances in lung transplantation for cystic fibrosis that may improve outcome. EJCTS 2010; 1-7.

10. O’Sullivan B, Freedman S. Cystic Fibrosis. Lancet 2009; 373: 1891–1904.

11. Rock M. Newborn Screening for Cystic Fibrosis. Clin Chest Med 2007; 28: 297–305.

12. Saiman L, Marshall B, Mayer-Hamblett N. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2003; 290: 1749–56.

13. Salvatore D, Buzzetti R. An overview of international literature from cystic fibrosis registries 2. Neonatal screening and nutrition/growth. J Cyst Fibros 2010; 9: 75–83.

14. Schelstraete P. Genotype based evaluation of Pseudomonas aeruginosa eradication treatment success in cystic fibrosis patients. J Cyst Fibros 2010; 99–103.

15. Seia M, Costantino L. Borderline sweat test: Utility and limits of genetic analysis for the diagnosis of cystic fibrosis. Clin Biochem 2009; 42: 611–6.

16. Sermet-Gaudelus I, Mayell S, Southern K. Guidelines on the early management of infants diagnosed with cystic fibrosis following newborn screening. J Cyst Fibros 2010; 9: 323–9.

17. Sims E, McCormick J, Mehta G, Mehta A. Newborn screening for cystic fibrosis is associated with reduced treatment intensity. J Pediatr 2005; 147: 306–11.

18. Stutman H, Lieberman J, Nussbaum E, Marks M. Antibiotic prophylaxis in infants and young children with cystic fibrosis: a randomized controlled trial. J Pediatr 2002; 140: 299–305.

19. Vrankrijker A. Challenging and emerging pathogens in cystic fibrosis. Paediatr Respir Rev 2010; 11: 246-54.

20. Wilcken B, Wiley V. Newborn screening methods for cystic fibrosis. Paediatr Respir Rev 2003; 4: 272–7.

21. Yousef A, Jaffe A. The Role of Azithromycin in Patients with Cystic Fibrosis. Paediatr Respir Rev 2010; 11: 108–14.